Sun Pharma announces tie-up for China foray; to develop 8 generic products

Sun Pharmaceutical Industries on Friday announced a partnership with China Medical System Holdings (CMS) to develop and commercialise generic drugs in mainland China. 

The tie-up will help the company make a foray into the generic drug market in China.

The collaboration with CMS covers eight generic products. The total addressable market size for all these eight products is about $1 billion (according to recent IQVIA data) in mainland China. The initial term of the agreement shall be 20 years from the first commercial sale of the respective products and may be extended for an additional three years’ according to a mutual agreement